Spots Global Cancer Trial Database for Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Official Title: A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Study ID: NCT04318080
Conditions
Interventions
Study Description
Brief Summary: The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall response rate per the Lugano Classification, and as determined by the investigator.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Karmanos Cancer Institute, Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Cancer Center, Bergen, New Jersey, United States
Memorial Sloan Kettering Cancer Center, Monmouth Junction, New Jersey, United States
Memorial Sloan Kettering Cancer Center, Commack, New York, United States
Memorial Sloan Kettering Cancer Center, Nassau, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, Westchester, New York, United States
University of TN Medical Center, Knoxville, Tennessee, United States
Huntsman Cancer Center, University of Utah, Salt Lake City, Utah, United States
Border Medical Oncology, Albury, New South Wales, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Monash Medical Center, Clayton, Victoria, Australia
Saint Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Institut Jules Bordet, Bruxelles, , Belgium
CHU de Liège - Domaine Universitaire du Sart Tilman, Liège, , Belgium
CHU UCL Namur - Site Godinne, Yvoir, , Belgium
Institut Gustave Roussy- Cancer Campus Grand Paris, Villejuif, Val De Marne, France
Institut d'Hematologie de Basse-Normandie, Caen, , France
Hopital Henri-Mondor, Créteil, , France
CHU Dijon Bourgogne, Dijon, , France
CHD de Vendee, La Roche-sur-Yon, , France
CH de Versailles - Hopital Andre Mignot, Le Chesnay, , France
CHRU de Lille- Hôpital Claude Huriez, Lille, , France
CHU de Limoges - Hopital Dupuytren, Limoges, , France
CHU de Montpellier, Montpellier, , France
CHU de Nantes, Nantes, , France
Hopital Saint-Louis, Paris, , France
CHU de Bordeaux Hopital Haut-Leveque, Pessac, , France
CHU Lyon-Sud, Pierre-Bénite, , France
Centre Henri-Becquerel, Rouen, , France
CHRU de Strasbourg, Strasbourg, , France
IUCT Oncopole, Toulouse, , France
CHU Brabois, Vandœuvre-lès-Nancy, , France
Hospital Oncologico-PR Med Ctr, Rio Piedras, , Puerto Rico
Contact Details
Name: Herve Ghesguieres
Affiliation: Lymphoma Study Association
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
